Myron E Schwartz
Overview
Explore the profile of Myron E Schwartz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
90
Citations
3800
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Marron T, Schwartz M, Miller E, Thanigaimani P, Lowy I, Thurston G, et al.
Lancet Gastroenterol Hepatol
. 2022 May;
7(6):505.
PMID: 35550051
No abstract available.
12.
Marron T, Fiel M, Hamon P, Fiaschi N, Kim E, Ward S, et al.
Lancet Gastroenterol Hepatol
. 2022 Jan;
7(3):219-229.
PMID: 35065058
Background: Surgical resection of early stage hepatocellular carcinoma is standard clinical practice; however, most tumours recur despite surgery, and no perioperative intervention has shown a survival benefit. Neoadjuvant immunotherapy has...
13.
Tabrizian P, Saberi B, Holzner M, Rocha C, Jung Y, Myers B, et al.
HPB (Oxford)
. 2021 Dec;
24(7):1082-1090.
PMID: 34955348
Background: The development of direct-acting antiviral (DAA) therapy has revolutionized HCV management. We present a large national study comparing post-LT outcomes for HBV-HCC vs. HCV-HCC according to DAA era. Methods:...
14.
Holzner M, Florman S, Schwartz M, Tabrizian P
HPB (Oxford)
. 2021 Sep;
24(4):470-477.
PMID: 34544629
Background: Nonalcoholic steatohepatitis-associated hepatocellular carcinoma (NASH-HCC) is the second-leading cause of liver transplantation (LT) performed for HCC. Despite this, little is known about the clinical characteristics and outcomes of NASH-HCC....
15.
Crouchet E, Bandiera S, Fujiwara N, Li S, El Saghire H, Fernandez-Vaquero M, et al.
Nat Commun
. 2021 Sep;
12(1):5525.
PMID: 34535664
Chronic liver disease and hepatocellular carcinoma (HCC) are life-threatening diseases with limited treatment options. The lack of clinically relevant/tractable experimental models hampers therapeutic discovery. Here, we develop a simple and...
16.
Tabrizian P, Florman S, Schwartz M
Am J Transplant
. 2020 Dec;
21(5):1979-1980.
PMID: 33316117
No abstract available.
17.
Woodrell C, Goldstein N, Moreno J, Schiano T, Schwartz M, Garrido M
J Pain Symptom Manage
. 2020 Oct;
61(5):940-947.e3.
PMID: 33035651
Context: Little is known about receipt of specialty-level palliative care by people with hepatocellular carcinoma (HCC) or its impact on health care utilization. Objectives: Identify patient characteristics associated with receipt...
18.
Simoes C, Thung S, Fiel M, Sung M, Schwartz M, Ward S
Mod Pathol
. 2020 Sep;
34(4):823-833.
PMID: 32989224
Nivolumab is an immune checkpoint inhibitor (ICI) approved for treatment of many cancers, including hepatocellular carcinoma (HCC). Liver injury is a known complication in patients treated with nivolumab for nonliver...
19.
Tarchi P, Di Renzo C, Tabrizian P, Rocha C, Schwartz M
Minerva Chir
. 2020 May;
75(4):272-274.
PMID: 32456393
No abstract available.
20.
Holzner M, Tabrizian P, Parvin-Nejad F, Fei K, Gunasekaran G, Rocha C, et al.
Liver Transpl
. 2020 May;
26(7):888-898.
PMID: 32352208
Mixed hepatocellular-cholangiocarcinoma (HCC-CC) is a biphenotypic liver cancer thought to have unfavorable tumor biology and a poor prognosis. Surgical outcomes of HCC-CC remain unclear. We aimed to evaluate the clinical...